Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.


Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
29 12 2020
Historique:
entrez: 18 1 2021
pubmed: 19 1 2021
medline: 29 7 2021
Statut: epublish

Résumé

Placenta-specific 1 (PLAC1) is expressed primarily in placental trophoblasts but not in normal tissues and is a targetable candidate for cancer immunotherapy because it is a cancer testis antigen known to be up-regulated in various tumors. Although peptide epitopes capable of stimulating CD8 T cells have been previously described, there have been no reports of PLAC1 CD4 helper T lymphocyte (HTL) epitopes and the expression of this antigen in head and neck squamous cell carcinoma (HNSCC). Here, we show that PLAC1 is highly expressed in 74.5% of oropharyngeal and 51.9% of oral cavity tumors from HNSCC patients and in several HNSCC established cell lines. We also identified an HTL peptide epitope (PLAC1

Identifiants

pubmed: 33457076
doi: 10.1080/2162402X.2020.1856545
pii: 1856545
pmc: PMC7781841
doi:

Substances chimiques

Antigens, Neoplasm 0
Epitopes, T-Lymphocyte 0
PLAC1 protein, human 0
Pregnancy Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1856545

Informations de copyright

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Cancer Immunol Immunother. 2014 Dec;63(12):1319-27
pubmed: 25186610
Blood. 2011 Jan 6;117(1):135-44
pubmed: 20889921
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24242-24251
pubmed: 31719197
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Cancer Res. 2007 Oct 1;67(19):9528-34
pubmed: 17909063
BMC Cancer. 2019 Mar 8;19(1):213
pubmed: 30849962
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Head Neck. 2008 Jan;30(1):75-84
pubmed: 17694557
PLoS One. 2018 Feb 12;13(2):e0192106
pubmed: 29432428
Cancer Immunol Res. 2017 Jan;5(1):72-83
pubmed: 27941004
Biol Blood Marrow Transplant. 2012 Aug;18(8):1302-8
pubmed: 22414493
Cancer Cell. 2004 May;5(5):489-500
pubmed: 15144956
Oncoimmunology. 2016 Mar 30;5(6):e1169356
pubmed: 27471649
Int J Gynecol Cancer. 2017 May;27(4):784-790
pubmed: 28375929
Nat Rev Cancer. 2005 Aug;5(8):615-25
pubmed: 16034368
Cancer. 2010 May 1;116(9):2071-80
pubmed: 20187092
Mol Oncol. 2018 Aug;12(8):1233-1248
pubmed: 29704427
Genomics. 2000 Sep 15;68(3):305-12
pubmed: 10995572
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Radiat Environ Biophys. 2011 Mar;50(1):145-54
pubmed: 21085979
Cancer Immunol Immunother. 2019 Jul;68(7):1039-1058
pubmed: 31165204
Cancer Immun. 2007 Nov 06;7:18
pubmed: 17983203
Immunity. 1994 Dec;1(9):751-61
pubmed: 7895164
Prenat Diagn. 2010 Jun;30(6):497-502
pubmed: 20509147
Int J Cancer. 2008 May 1;122(9):2038-43
pubmed: 18183594
Gastroenterology. 2008 Apr;134(4):998-1006
pubmed: 18395081
Oncol Rep. 2018 Jan;39(1):53-60
pubmed: 29138842
Cancer Immunol Immunother. 2015 Jun;64(6):697-705
pubmed: 25754123
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Obstet Gynecol Int. 2013;2013:807849
pubmed: 23935632
Cancer Immunol Immunother. 2020 Jun;69(6):989-999
pubmed: 32086539
J Clin Pathol. 2015 Nov;68(11):913-6
pubmed: 26157147
Cancer Res. 2000 Sep 15;60(18):5228-36
pubmed: 11016652
Cancer Immun. 2009 Aug 26;9:6
pubmed: 19705800
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Int Immunol. 2016 Jul;28(7):319-28
pubmed: 27235694
Sci Rep. 2018 Apr 9;8(1):5717
pubmed: 29632317
J Gastroenterol. 2014 Mar;49(3):419-26
pubmed: 23604623
Cancer Immun. 2012;12:16
pubmed: 23390371
Curr Opin Immunol. 2017 Aug;47:57-63
pubmed: 28734176
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Oncol Rep. 2017 Jan;37(1):465-473
pubmed: 27878289
Cancer Immunol Immunother. 2020 May;69(5):859-865
pubmed: 31915853
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
Clin Cancer Res. 2005 May 15;11(10):3869-78
pubmed: 15897588
Int J Oncol. 2017 May;50(5):1721-1728
pubmed: 28339050
J Transl Med. 2019 Jun 20;17(1):207
pubmed: 31221178
J Immunol. 2000 Dec 1;165(11):6047-55
pubmed: 11086036
Oncol Lett. 2018 Apr;15(4):5924-5932
pubmed: 29556312
Tumour Biol. 2017 Jun;39(6):1010428317699131
pubmed: 28618924
Nature. 2003 Feb 20;421(6925):852-6
pubmed: 12594515
J Biomed Biotechnol. 2011;2011:954602
pubmed: 22174559
Cell. 2020 Jun 25;181(7):1612-1625.e13
pubmed: 32497499
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Amino Acids. 2012 Jun;42(6):2257-65
pubmed: 21710262
Oncoimmunology. 2018 Aug 1;7(9):e1466771
pubmed: 30510853
Cancer Immunol Immunother. 2013 Apr;62(4):787-99
pubmed: 23266830
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Curr Opin Immunol. 2017 Apr;45:1-7
pubmed: 27940327
Cancer Immunol Immunother. 2019 Mar;68(3):455-466
pubmed: 30604041
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862

Auteurs

Ryusuke Hayashi (R)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Toshihiro Nagato (T)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Takumi Kumai (T)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan.

Kenzo Ohara (K)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Mizuho Ohara (M)

Department of Surgery, Asahikawa Medical University, Asahikawa, Japan.

Takayuki Ohkuri (T)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Yui Hirata-Nozaki (Y)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Shohei Harabuchi (S)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Akemi Kosaka (A)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Marino Nagata (M)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Yuki Yajima (Y)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Department of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Japan.

Syunsuke Yasuda (S)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.
Respiratory and Breast Center, Asahikawa Medical University Hospital, Asahikawa, Japan.

Kensuke Oikawa (K)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Michihisa Kono (M)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Kan Kishibe (K)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Miki Takahara (M)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Akihiro Katada (A)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Tatsuya Hayashi (T)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.
Department of Innovative Research for Diagnosis and Treatment of Head and Neck Cancer, Asahikawa Medical University, Asahikawa, Japan.

Esteban Celis (E)

Cancer Immunology, Inflammation and Tolerance Program, Augusta University, Georgia Cancer Center, Augusta, GA, USA.

Yasuaki Harabuchi (Y)

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Hiroya Kobayashi (H)

Department of Pathology, Asahikawa Medical University, Asahikawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH